Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1065-1071

  Yun, Huifeng ^a,b   Xie, Fenglong ^b   Delzell, Elizabeth ^a   Chen, Lang ^b   Levitan, Emily B ^a   Lewis, James D ^c   Saag, Kenneth G ^b   Beukelman, Timothy ^b   Winthrop, Kevin ^d   Baddley, John W ^e   Curtis, Jeffrey R ^a,b   Kvien, Tore K ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e University of Alabama at Birmingham   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COHORT ANALYSIS; HOSPITALIZATION; PROPORTIONAL HAZARDS MODEL; RESPIRATORY TRACT INFECTIONS; RISK; SEPSIS; SOFT TISSUE INFECTIONS; STATISTICS AND NUMERICAL DATA; UNITED STATES; URINARY TRACT INFECTIONS; VERY ELDERLY;

ABATACEPT; ADALIMUMAB; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; ETANERCEPT; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; MEDICARE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; RESPIRATORY TRACT INFECTIONS; RISK; RITUXIMAB; SEPSIS; SOFT TISSUE INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84935001577     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204011     Document Type: Article

References (31)

1. Doran MF, Crowson CS, Pond G.R., et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46:2294-300.
2. Capell HA. Disease modifying antirheumatic drugs: longterm safety issues. J Rheumatol Suppl 2001; 62:10-15.
3. Grijalva CG, Chen L, Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306:2331-9.
4. Curtis JR, Patkar N, Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125-33.
5. Curtis JR, Xie F, Chen L., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011; 70:1401-6.
6. Curtis JR, Xi J, Patkar N., et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:4226-7.
7. Dixon WG, Hyrich KL, Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2009; 69:522-8.
8. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56:2896-904.
9. Johnston SS, Turpcu A, Shi N., et al. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum 2013:43:39-47.
10. Schneeweiss S, Setoguchi S, Weinblatt M.E., et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:1754-64.
11. Listing J, Strangfeld A, Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-12.
12. Dewedar AM, Shalaby MA, Al-Homaid S, et al. Lack of adverse effect of anti-tumor necrosis factor-alpha biologics in treatment of rheumatoid arthritis: 5 years follow-up. Int J Rheum Dis 2012; 15:330-5.
13. Keyser FD. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Current Rheumatol Rev 2011; 7:77-87.
14. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39:327-46.
15. Hyrich KL, Lunt M, Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13-20.
16. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625-39.
17. Medicare at a Glance fact sheet | The Henry J. Kaiser Family Foundation, http://kff.org/medicare/fact-sheet/medicare-at-a-glance-fact-sheet/ (retrieved on 19 September 2013).
18. Social Security, Disability Evaluation Under Social Secuity. http://www.ssa.gov/disability/professionals/bluebook/14.00-Immune-Adult.htm#14-09. (retrieved on 31 January 2014).
19. Patkar NM, Curtis JR, Teng G.G., et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009; 62:321-7, 7 e1-7.
20. Curtis JR, Xie F, Chen L., et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64:1480-9.
21. Glynn RJ, Gayne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012; 21 (S2):238-47.
22. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84:1074-8.
23. Gentleman R, Hess KR. Hazard Function Estimation in Survival Analysis. 2010. http://cran.r-project.org/web/packages/muhaz/muhaz.pdf (accessed 17 May 2013).
24. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med 1999; 18:3075-88.
25. Dixon WG, Hyrich KL, Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-8.
26. Strangfeld A, Eveslage M, Schneider M., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70:1914-20.
27. Schiff M, Keiserman M, Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67:1096-103.
28. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014; 73:86-94.
29. van Dartel SA, Fransen J, Kievit W., et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72:895-900.
30. Singh JA, Christensen R, Wells G.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181:787-96.
31. Curtis JR, Martin C, Saag K.G., et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. Arthritis Rheum 2007; 57:343-6.